SCHEMBL2212378

SCHEMBL2212378

COc1ccc(-c2ccc(-c3cc4ccnn4c(Nc4ccc(NC(=O)c5ccc(CN)cc5)cc4)n3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.49
PLAU P00749 2/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LOX P28300 2/20 0.44
LOXL2 Q9Y4K0 2/20 0.44
KLKB1 P03952 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 2/20 0.42
ALOX15 P16050 1/20 0.42
MCHR1 Q99705 1/20 0.42
HIF1A Q16665 1/20 0.42
EPAS1 Q99814 1/20 0.42
LMNA P02545 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
PLG P00747 3/20 0.42
MAPT P10636 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2214607 0.95 PLAU (0.46) SNCAPLAUNPC1RAB9AMEN1
SCHEMBL2215189 0.94 PLAU (0.50) SNCAPLAUNPC1MEN1KMT2A
SCHEMBL2213866 0.93 PLG (0.47) SNCAPLAULOXLOXL2KLKB1
SCHEMBL2211981 0.90 HDAC1 (0.45) PLAUMEN1KMT2ALOXLOXL2
SCHEMBL2214976 0.89 MAPT (0.47) PLAUNPC1MEN1KMT2ALOX
SCHEMBL2215297 0.89 PTPN1 (0.45) PLAUNPC1RAB9AMEN1KMT2A
SCHEMBL2213349 0.88 PLAU (0.48) SNCAPLAUNPC1MEN1KMT2A
SCHEMBL2216236 0.88 KLKB1 (0.41) SNCAPLAUNPC1RAB9AMEN1
SCHEMBL2215216 0.88 PLAU (0.41) SNCAPLAUMEN1KMT2ALOXL2
SCHEMBL2216054 0.87 PLAU (0.39) SNCAPLAULOXLOXL2KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 SNCA 4002/4885PLAU 4610/4885NPC1 3449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.